Back to results
US 12,427,190 B2Granted
VLP-based monovalent ebola vaccines and methods of making and using same
AssigneeChildren's Hospital Medical Center
InventorsXuemin Chen, Karnail Singh, Paul Spearman
Life of this patent
Estimating the term…
Abstract
Disclosed herein are virus-like particle (VLP)-based monovalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and a single Ebola glycoprotein selected from either a Zaire (EBOV) glycoprotein or a Sudan (SUDV) glycoprotein. The Ebola glycoprotein may be incorporated into the surface of the spherical Gag core, wherein said VLP-based vaccine presents a single Ebola glycoprotein antigen.
Claims24
A virus-like particle (VLP)-based monovalent vaccine composition comprising
- a spherical retroviral Group-specific Antigen (“Gag”) protein core;
- and
- an Ebola glycoprotein selected from either a full-length Zaire (EBOV) glycoprotein or a full-length Sudan (SUDV) glycoprotein,
- said Ebola glycoprotein being incorporated into the surface of said spherical retroviral Gag protein core in a native conformation;
- said VLP-based monovalent vaccine having an EBOV glycoprotein, said EBOV glycoprotein having a density at the surface of the spherical retroviral Gag protein core of about 20 to about 200 μg/mL or an SUDV glycoprotein, said SUDV glycoprotein having a density at the surface of the spherical retroviral Gag protein core of about 10 to about 60 μg/mL.
2 more elements
Dependencies are inferred from the claim text.